BSE Live
Apr 16, 16:01Prev. Close
55.17
Open Price
64.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Balance Sheet of OXYGENTA PHARMACEUTICAL (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 36.98 | 33.48 | 14.20 | 14.20 | 10.20 | |
| Total Share Capital | 36.98 | 33.48 | 14.20 | 14.20 | 10.20 | |
| Reserves and Surplus | -62.01 | -54.17 | -60.40 | -48.83 | -48.22 | |
| Total Reserves and Surplus | -62.01 | -54.17 | -60.40 | -48.83 | -48.22 | |
| Total Shareholders Funds | -25.02 | -20.12 | -46.20 | -34.63 | -38.02 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 21.52 | 49.00 | 63.02 | 51.04 | 45.04 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 1.66 | 2.53 | 1.34 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 3.07 | 4.20 | 8.01 | |
| Long Term Provisions | 1.08 | 0.62 | 2.90 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 22.60 | 49.62 | 70.65 | 57.76 | 54.39 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 40.71 | 8.23 | 4.97 | 1.09 | 2.85 | |
| Trade Payables | 29.79 | 22.89 | 23.78 | 6.46 | 13.79 | |
| Other Current Liabilities | 15.11 | 2.58 | 0.54 | 0.38 | 0.77 | |
| Short Term Provisions | 0.23 | 0.00 | 0.52 | 0.12 | 0.09 | |
| Total Current Liabilities | 85.85 | 33.70 | 29.82 | 8.04 | 17.50 | |
| Total Capital And Liabilities | 83.42 | 63.19 | 54.26 | 31.18 | 33.86 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 39.63 | 29.36 | 27.91 | 19.98 | 16.31 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.23 | 0.00 | 0.00 | 0.34 | 0.65 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 39.86 | 29.36 | 27.91 | 20.32 | 16.97 | |
| Non-Current Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Deferred Tax Assets [Net] | 10.80 | 8.73 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.42 | 0.42 | 0.42 | 0.35 | |
| Other Non-Current Assets | 1.76 | 0.53 | 0.88 | 0.82 | 0.56 | |
| Total Non-Current Assets | 52.48 | 39.09 | 29.26 | 21.61 | 17.92 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 20.51 | 13.72 | 11.71 | 7.28 | 12.11 | |
| Trade Receivables | 5.10 | 7.36 | 10.16 | 1.58 | 1.61 | |
| Cash And Cash Equivalents | 0.12 | 0.10 | 0.11 | 0.16 | 0.45 | |
| Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | |
| OtherCurrentAssets | 5.21 | 2.93 | 3.04 | 0.55 | 1.74 | |
| Total Current Assets | 30.94 | 24.11 | 25.01 | 9.56 | 15.94 | |
| Total Assets | 83.42 | 63.19 | 54.26 | 31.18 | 33.86 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 3.41 | 0.00 | 0.00 | 1.20 | 1.20 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 8.07 | 0.01 | 0.00 | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | 0.14 | 0.04 | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 0.05 | 0.05 | 0.05 | 0.05 | -- | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
09.02.2026
OXYGENTA PHARMA Standalone December 2025 Net Sales at Rs 33.93 crore, up 2.18% Y-o-Y
12.11.2025
OXYGENTA PHARMA Standalone September 2025 Net Sales at Rs 14.30 crore, up 2.12% Y-o-Y
11.06.2025
OXYGENTA PHARMA Standalone March 2025 Net Sales at Rs 49.47 crore, up 368.77% Y-o-Y
25.11.2024
OXYGENTA PHARMA Standalone September 2024 Net Sales at Rs 14.01 crore, up 7.11% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth